MDACC Study No:2009-0625 ( NCT No: NCT01193517)
Title:Phase I/II Study of Azacitidine and CAPOX (Capecitabine + Oxaliplatin) in Metastatic Colorectal Cancer Patients Enriched for Hypermethylation of CpG Promoter Islands
Principal Investigator:Michael Overman
Treatment Agent:Azacitidine; Capecitabine; Oxaliplatin
Study Status:Closed
Study Description:The goal of the Phase I portion of this study is to find the highest tolerable
dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can
be given to patients with metastatic colorectal cancer.

The goal of the Phase II portion of this study is to learn if azacitidine,
given in combination with CAPOX, can help to control metastatic colorectal
cancer. The safety of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Colorectum
Phase of Study:Phase I/Phase II
Treatment Agents:Azacitidine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:NA
Supported By:Celgene
Return Visit:Every 3 weeks.
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Overman
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults